Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

496
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
496
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

196
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
196
Depression: Overview01:18

Depression: Overview

254
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
254
Dementia01:30

Dementia

117
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
117
Long-term Depression01:03

Long-term Depression

2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.5K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

103
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
103

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining neuroretinal alterations in autism spectrum disorder: a systematic review of OCT and OCT-A studies.

International journal of psychiatry in clinical practice·2026
Same author

Predicting early clinical recovery in first-episode psychosis: development and external validation of a clinically interpretable multivariable model.

The British journal of psychiatry : the journal of mental science·2026
Same author

Differences across males and females in cognitive aging and mortality risk: a trajectory-based approach.

GeroScience·2026
Same author

From premorbid adjustment dimensions to clinical outcomes: Exploring environmental stress and epigenetic influences on first-episode schizophrenia phenotypes.

Spanish journal of psychiatry and mental health·2025
Same author

Polygenic risk score of glycemic homeostasis, Type 2 Diabetes Mellitus and glycemic components in first episode psychosis.

Schizophrenia research·2025
Same author

Clinical parameters predicted the progression to dementia in oldest old patients with mild cognitive impairment (MCI).

International psychogeriatrics·2025

Related Experiment Video

Updated: Jul 11, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K

The Interface between Depression and Alzheimer's Disease. A Comprehensive Approach.

Pedro J Modrego1, Leyre D de Cerio1, Antonio Lobo2

  • 1Servicio de Neurologia, Hospital Miguel Servet de Zaragoza, Spain.

Annals of Indian Academy of Neurology
|November 16, 2023
PubMed
Summary

Depression in Alzheimer's disease (AD) patients shows controversial antidepressant response, with no significant difference from placebo. Neuroinflammation may link depression and AD, but amyloid deposition is not a clear factor. Further research is needed.

Keywords:
Alzheimer diseasedepressionrandomized trials

More Related Videos

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

663
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

7.9K

Related Experiment Videos

Last Updated: Jul 11, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

663
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

7.9K

Area of Science:

  • Neuroscience
  • Geriatrics
  • Psychiatry

Background:

  • Depression and Alzheimer's disease (AD) frequently co-occur in the elderly, significantly impacting patient and caregiver quality of life.
  • Late-life depression can be an early symptom or a risk factor for AD, highlighting a complex relationship.

Purpose of the Study:

  • To review recent advancements in understanding the neurobiological underpinnings of depression in AD.
  • To evaluate the efficacy of antidepressant treatments for depression in Alzheimer's disease patients.

Main Methods:

  • Systematic review of neurobiological hypotheses, including neuroinflammation and dysimmune regulation.
  • Analysis of 10 small double-blind randomized placebo-controlled trials involving 638 patients treated with various antidepressants (sertraline, mirtazapine, fluoxetine, imipramine, clomipramine, escitalopram, vortioxetine).

Main Results:

  • Evidence suggests neuroinflammation and dysimmune regulation may be linked to depression in AD, while the role of amyloid deposition remains unresolved.
  • Meta-analysis of clinical trials (weighted OR: 1.29; 95% CI: 0.77-2.16) showed no significant difference in antidepressant efficacy compared to placebo for depression in AD.
  • Antidepressants did not negatively impact cognition as measured by the Mini-Mental State Examination (MMSE) in 18 clinical trials.

Conclusions:

  • Current antidepressant treatments show controversial efficacy for depression in Alzheimer's disease patients.
  • Neurobiological factors like neuroinflammation warrant further investigation.
  • Alternative therapeutic strategies beyond medication require additional research.